IA
EDIT icon

IFP Advisors’s Editas Medicine EDIT Stock Holding History

IFP Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.64K Buy
506
+99
+24% +$289 ﹤0.01% 4322
2026
Q1 		$1K Buy
407
+361
+785% +$764 ﹤0.01% 4215
2025
Q4 		$94 Sell
46
-8
-15% -$23 ﹤0.01% 4604
2025
Q3 		$187 Sell
54
-4,982
-99% -$13.9K ﹤0.01% 4411
2025
Q2 		$11.1K Buy
5,036
+36
+0.7% +$59 ﹤0.01% 2855
2025
Q1 		$5.8K Buy
5,000
+4,966
+14,606% +$7.3K ﹤0.01% 2782
2024
Q4 		$43 Buy
+34
New +$87 ﹤0.01% 4297
2023
Q3 		– Sell
-49
Closed -$403 – 3368
2023
Q2 		$403 Buy
+49
New +$427 ﹤0.01% 3227
2023
Q1 		– Sell
-706
Closed -$26K – 3660
2022
Q4 		$26K Sell
706
-268
-28% -$2.94K ﹤0.01% 2686
2022
Q3 		$47K Hold
974
– – ﹤0.01% 2408
2022
Q2 		$47K Hold
974
– – ﹤0.01% 2206
2022
Q1 		$47K Buy
974
+817
+520% +$15.2K ﹤0.01% 2206
2021
Q4 		$5K Sell
157
-52
-25% -$1.79K ﹤0.01% 2478
2021
Q3 		$9K Buy
209
+200
+2,222% +$11K ﹤0.01% 2316
2021
Q2 		$1K Hold
9
– – ﹤0.01% 2883
2021
Q1 		$0 Hold
9
– – ﹤0.01% 3055
2020
Q4 		$1K Hold
9
– – ﹤0.01% 2745
2020
Q3 		$0 Sell
9
-1
-10% -$33 ﹤0.01% 2874
2020
Q2 		$0 Hold
10
– – ﹤0.01% 2779
2020
Q1 		$0 Sell
10
-196
-95% -$4.94K ﹤0.01% 2815
2019
Q4 		$6K Sell
206
-656
-76% -$16.4K ﹤0.01% 2110
2019
Q3 		$19K Buy
+862
New +$21.4K ﹤0.01% 1780
2019
Q1 		$28K Buy
1,131
+115
+11% +$2.6K ﹤0.01% 1192
2018
Q4 		$21K Buy
1,016
+164
+19% +$4.46K ﹤0.01% 2100
2018
Q3 		$27K Sell
852
-26
-3% -$840 ﹤0.01% 2278
2018
Q2 		$31K Sell
878
-154
-15% -$5.45K ﹤0.01% 2197
2018
Q1 		$32K Hold
1,032
– – ﹤0.01% 2065
2017
Q4 		$32K Sell
1,032
-654
-39% -$16.5K ﹤0.01% 2090
2017
Q3 		$40K Buy
1,686
+1,300
+337% +$24.7K ﹤0.01% 2124
2017
Q2 		$6K Hold
386
– – ﹤0.01% 3293
2017
Q1 		$9K Buy
+386
New +$8K ﹤0.01% 2974
2016
Q2 		– Sell
-1,131
Closed -$28K – 3879
2016
Q1 		$28K Buy
+1,131
New +$29.7K ﹤0.01% 1192

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

IFP Advisors's EDIT Position: Q2 2026 in Review

IFP Advisors increased its Editas Medicine (EDIT) stake by 24% in Q2 2026, buying an estimated $289 and bringing the position to 506 shares worth $1.64K. The position accounts for ﹤0.01% of the portfolio, ranked #4322.

IFP Advisors first reported a position in EDIT in Q1 2016 and has held it in 32 quarters since. The position peaked at $47K in Q3 2022. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • IFP Advisors held 506 shares of Editas Medicine worth $1.64K as of Q2 2026.
  • IFP Advisors bought 99 Editas Medicine shares in Q2 2026, an estimated $289.
  • Editas Medicine made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4322 holding.
  • IFP Advisors first reported a position in Editas Medicine in Q1 2016 and has held it in 32 quarters since.
  • IFP Advisors's Editas Medicine position peaked at $47K in Q3 2022.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.